Integrative insights into the role of CAV1 in ketogenic diet and ferroptosis in pancreatic cancer.
Study Goal
The researchers aimed to investigate the molecular mechanisms by which the ketogenic diet induces ferroptosis in pancreatic cancer cells, focusing on the role of CAV1.
Results Summary
The study found that the ketogenic diet downregulated CAV1, leading to ferroptosis in pancreatic cancer cells through Fe2+ overload and lipid peroxidation. In mouse models, the diet increased ferroptosis biomarkers while reducing CAV1 and SLC7A11 levels.
Population
Pancreatic adenocarcinoma (PAAD) tissues and tumor-bearing mouse models.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ketogenic diet | increase | ferroptosis in cancer cells | pancreatic cancer | - | may act as adjuvant therapy by triggering ferroptosis | #1 |
- | increase | ketogenic and ferroptosis phenotypes | pancreatic adenocarcinoma (PAAD) tissues | - | significantly enhanced | #2 |
- | neutral | ketogenic and ferroptosis phenotypes | patients | - | correlating with poorer patient prognosis | #3 |
Na-OHB | decrease | CAV1 expression | pancreatic cancer cells | - | downregulated | #4 |
Na-OHB | decrease | CAV1/AMPK/NRF2 downstream ferroptosis-protective genes SLC7A11 and SLC40A1 | pancreatic cancer cells | - | inhibiting the transcription | #5 |
CAV1 downregulation | decrease | SLC7A11 protein | - | - | affected the stability of SLC7A11, leading to the ubiquitination and degradation | #6 |
Na-OHB | increase | Fe2+ overload, lipid peroxidation accumulation, and oxidative stress | pancreatic cancer cells | - | caused | #7 |
Na-OHB | increase | ferroptosis | pancreatic cancer cells | - | ultimately triggering | #8 |
ketogenic diet | increase | lipid peroxidation and other related biomarkers | tumor-bearing mouse models | - | significant increase | #9 |
ketogenic diet | decrease | CAV1 and SLC7A11 levels | tumor-bearing mouse models | - | markedly decreased | #10 |
Pancreatic cancer exhibits high mortality rates with limited therapeutic options. Emerging evidence suggests that the ketogenic diet may act as adjuvant therapy by triggering ferroptosis in cancer cells, though the underlying molecular mechanisms remain unclear. This study aims to investigate the molecular mechanisms linking ketogenic metabolism and ferroptosis, with an emphasis on key regulatory proteins. We demonstrated that pancreatic adenocarcinoma (PAAD) tissues significantly enhanced ketogenic and ferroptosis phenotypes compared to normal tissues, both correlating with poorer patient prognosis. These phenotypes showed strong interdependence mediated by CAV1. In the pancreatic tumor microenvironment, CAV1 was predominantly expressed in tumor cells. Through in vitro cell experiments, we clarified that Na-OHB downregulated CAV1 expression in pancreatic cancer cells, inhibiting the transcription of the CAV1/AMPK/NRF2 downstream ferroptosis-protective genes SLC7A11 and SLC40A1. Additionally, we demonstrated the interaction between CAV1 and SLC7A11 molecules; when CAV1 was downregulated, it affected the stability of SLC7A11, leading to the ubiquitination and degradation of the translated SLC7A11 protein. Through these dual mechanisms, Na-OHB caused Fe2+ overload, lipid peroxidation accumulation, and oxidative stress in pancreatic cancer cells, ultimately triggering ferroptosis. In ketogenic diet-fed tumor-bearing mouse models, we also observed a significant increase in lipid peroxidation and other related biomarkers, while CAV1 and SLC7A11 levels were markedly decreased compared to the normal diet group. Our findings identify CAV1 as a pivotal molecular link between ketogenic metabolism and ferroptosis in pancreatic cancer. The multi-level regulatory axis involving CAV1-mediated transcriptional regulation and post-translational modifications provides mechanistic insights into ketogenic diet-induced ferroptosis, suggesting potential therapeutic targets for pancreatic cancer adjuvant treatment.